Compare RLAY & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLAY | ABCL |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2020 | 2020 |
| Metric | RLAY | ABCL |
|---|---|---|
| Price | $19.35 | $12.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $19.50 | $8.40 |
| AVG Volume (30 Days) | 2.8M | ★ 4.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | $15,355,000.00 | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 53.44 | ★ 160.56 |
| 52 Week Low | $4.32 | $2.75 |
| 52 Week High | $21.27 | $13.18 |
| Indicator | RLAY | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 65.43 |
| Support Level | $18.03 | $10.38 |
| Resistance Level | $20.82 | N/A |
| Average True Range (ATR) | 0.69 | 0.59 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 20.12 | 79.02 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.